Ardea Biosciences completes public offering

NewsGuard 100/100 Score

Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced the completion of a public offering of 4,025,000 shares of its common stock, including 525,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the shares were offered by Ardea Biosciences.  The net proceeds to Ardea Biosciences from the sale of shares in the offering, after deducting underwriting discounts and commissions, were approximately $77.1 million.

Jefferies & Company, Inc. acted as sole book-running manager in the offering.  The joint lead manager in the offering was Oppenheimer & Co.

A registration statement relating to the shares issued in the offering has been filed with, and declared effective by, the Securities and Exchange Commission. A final prospectus supplement relating to the offering has been filed with the Securities and Exchange Commission.

SOURCE Ardea Biosciences, Inc.

Posted in:

Tags: ,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.